Special Issue

Advances in Urological Cancer: Innovative Therapies and Biomarkers

Message from the Guest Editor

This Special Issue focuses on cutting-edge research in urological oncology, emphasizing prostate, urothelial, and kidney cancers. It features innovative therapeutic strategies, novel biomarkers for detection and prognosis, and translational studies bridging bench to bedside. Contributions explore immunotherapy, targeted therapies, liquid biopsies, and Al-driven diagnostics. 's work on early dynamic changes in albumin and the systemic immune-inflammation index (SII) (Δ Alb + Δ SII), which may have the potential to serve as predictors of progression-free survival in cabozantinib-treated mRCC after immune checkpoint inhibitor (ICI) therapy highlights clinical relevance. This issue aims to accelerate precision medicine in urological cancers.

Guest Editor

Dr. Hiroshi Yaegashi

Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, 13-1 Takara-machi, Kanazawa 920-8641, Ishikawa, Japan

Deadline for manuscript submissions

31 May 2026



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/261096

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

